1
|
Lidani KCF, Buscaglia R, Trainor PJ, Tomar S, Kaliappan A, DeFilippis AP, Garbett NC. Characterization of myocardial injury phenotype by thermal liquid biopsy. Front Cardiovasc Med 2024; 11:1342255. [PMID: 38638880 PMCID: PMC11024444 DOI: 10.3389/fcvm.2024.1342255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 03/18/2024] [Indexed: 04/20/2024] Open
Abstract
Background and aims With the advent and implementation of high-sensitivity cardiac troponin assays, differentiation of patients with distinct types of myocardial injuries, including acute thrombotic myocardial infarction (TMI), acute non-thrombotic myocardial injury (nTMi), and chronic coronary atherosclerotic disease (cCAD), is of pressing clinical importance. Thermal liquid biopsy (TLB) emerges as a valuable diagnostic tool, relying on identifying thermally induced conformational changes of biomolecules in blood plasma. While TLB has proven useful in detecting and monitoring several cancers and autoimmune diseases, its application in cardiovascular diseases remains unexplored. In this proof-of-concept study, we sought to determine and characterize TLB profiles in patients with TMI, nTMi, and cCAD at multiple acute-phase time points (T 0 h, T 2 h, T 4 h, T 24 h, T 48 h) as well as a follow-up time point (Tfu) when the patient was in a stable state. Methods TLB profiles were collected for 115 patients (60 with TMI, 35 with nTMi, and 20 with cCAD) who underwent coronary angiography at the event presentation and had subsequent follow-up. Medical history, physical, electrocardiographic, histological, biochemical, and angiographic data were gathered through medical records, standardized patient interviews, and core laboratory measurements. Results Distinctive signatures were noted in the median TLB profiles across the three patient types. TLB profiles for TMI and nTMi patients exhibited gradual changes from T0 to Tfu, with significant differences during the acute and quiescent phases. During the quiescent phase, all three patient types demonstrated similar TLB signatures. An unsupervised clustering analysis revealed a unique TLB signature for the patients with TMI. TLB metrics generated from specific features of TLB profiles were tested for differences between patient groups. The first moment temperature (TFM) metric distinguished all three groups at time of presentation (T0). In addition, 13 other TLB-derived metrics were shown to have distinct distributions between patients with TMI and those with cCAD. Conclusion Our findings demonstrated the use of TLB as a sensitive and data-rich technique to be explored in cardiovascular diseases, thus providing valuable insight into acute myocardial injury events.
Collapse
Affiliation(s)
- Karita C. F. Lidani
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Robert Buscaglia
- Department of Mathematics and Statistics, Northern Arizona University, Flagstaff, AZ, United States
| | - Patrick J. Trainor
- Department of Chemistry and Biochemistry, New Mexico State University, Las Cruces, NM, United States
- Molecular Biology and Interdisciplinary Life Sciences Program, New Mexico State University, Las Cruces, NM, United States
| | - Shubham Tomar
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Alagammai Kaliappan
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY, United States
| | - Andrew P. DeFilippis
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States
| | - Nichola C. Garbett
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY, United States
| |
Collapse
|
2
|
Nguyen TQ, Schneider G, Kaliappan A, Buscaglia R, Brock GN, Hall MB, Miller DM, Chesney JA, Garbett NC. Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients. Curr Oncol 2023; 30:6079-6096. [PMID: 37504313 PMCID: PMC10378067 DOI: 10.3390/curroncol30070453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2023] [Revised: 05/31/2023] [Accepted: 06/21/2023] [Indexed: 07/29/2023] Open
Abstract
Melanoma is the fifth most common cancer in the United States and the deadliest of all skin cancers. Even with recent advancements in treatment, there is still a 13% two-year recurrence rate, with approximately 30% of recurrences being distant metastases. Identifying patients at high risk for recurrence or advanced disease is critical for optimal clinical decision-making. Currently, there is substantial variability in the selection of screening tests and imaging, with most modalities characterized by relatively low accuracy. In the current study, we built upon a preliminary examination of differential scanning calorimetry (DSC) in the melanoma setting to examine its utility for diagnostic and prognostic assessment. Using regression analysis, we found that selected DSC profile (thermogram) parameters were useful for differentiation between melanoma patients and healthy controls, with more complex models distinguishing melanoma patients with no evidence of disease from patients with active disease. Thermogram features contributing to the third principal component (PC3) were useful for differentiation between controls and melanoma patients, and Cox proportional hazards regression analysis indicated that PC3 was useful for predicting the overall survival of active melanoma patients. With the further development and optimization of the classification method, DSC could complement current diagnostic strategies to improve screening, diagnosis, and prognosis of melanoma patients.
Collapse
Affiliation(s)
- Taylor Q. Nguyen
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Gabriela Schneider
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Alagammai Kaliappan
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Robert Buscaglia
- Department of Mathematics and Statistics, Northern Arizona University, Flagstaff, AZ 86011, USA
| | - Guy N. Brock
- Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA
| | - Melissa Barousse Hall
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Donald M. Miller
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Jason A. Chesney
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| | - Nichola C. Garbett
- UofL Health–Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
| |
Collapse
|
3
|
Baksheeva VE, Tiulina VV, Iomdina EN, Petrov SY, Filippova OM, Kushnarevich NY, Suleiman EA, Eyraud R, Devred F, Serebryakova MV, Shebardina NG, Chistyakov DV, Senin II, Mitkevich VA, Tsvetkov PO, Zernii EY. Tear nanoDSF Denaturation Profile Is Predictive of Glaucoma. Int J Mol Sci 2023; 24:ijms24087132. [PMID: 37108298 PMCID: PMC10139145 DOI: 10.3390/ijms24087132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Revised: 04/07/2023] [Accepted: 04/08/2023] [Indexed: 04/29/2023] Open
Abstract
Primary open-angle glaucoma (POAG) is a frequent blindness-causing neurodegenerative disorder characterized by optic nerve and retinal ganglion cell damage most commonly due to a chronic increase in intraocular pressure. The preservation of visual function in patients critically depends on the timeliness of detection and treatment of the disease, which is challenging due to its asymptomatic course at early stages and lack of objective diagnostic approaches. Recent studies revealed that the pathophysiology of glaucoma includes complex metabolomic and proteomic alterations in the eye liquids, including tear fluid (TF). Although TF can be collected by a non-invasive procedure and may serve as a source of the appropriate biomarkers, its multi-omics analysis is technically sophisticated and unsuitable for clinical practice. In this study, we tested a novel concept of glaucoma diagnostics based on the rapid high-performance analysis of the TF proteome by differential scanning fluorimetry (nanoDSF). An examination of the thermal denaturation of TF proteins in a cohort of 311 ophthalmic patients revealed typical profiles, with two peaks exhibiting characteristic shifts in POAG. Clustering of the profiles according to peaks maxima allowed us to identify glaucoma in 70% of cases, while the employment of artificial intelligence (machine learning) algorithms reduced the amount of false-positive diagnoses to 13.5%. The POAG-associated alterations in the core TF proteins included an increase in the concentration of serum albumin, accompanied by a decrease in lysozyme C, lipocalin-1, and lactotransferrin contents. Unexpectedly, these changes were not the only factor affecting the observed denaturation profile shifts, which considerably depended on the presence of low-molecular-weight ligands of tear proteins, such as fatty acids and iron. Overall, we recognized the TF denaturation profile as a novel biomarker of glaucoma, which integrates proteomic, lipidomic, and metallomic alterations in tears, and monitoring of which could be adapted for rapid non-invasive screening of the disease in a clinical setting.
Collapse
Affiliation(s)
- Viktoriia E Baksheeva
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, 119992 Moscow, Russia
- Institut Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
| | - Veronika V Tiulina
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, 119992 Moscow, Russia
| | - Elena N Iomdina
- Helmholtz National Medical Research Center of Eye Diseases, 105062 Moscow, Russia
| | - Sergey Yu Petrov
- Helmholtz National Medical Research Center of Eye Diseases, 105062 Moscow, Russia
| | - Olga M Filippova
- Helmholtz National Medical Research Center of Eye Diseases, 105062 Moscow, Russia
| | - Nina Yu Kushnarevich
- Helmholtz National Medical Research Center of Eye Diseases, 105062 Moscow, Russia
| | - Elena A Suleiman
- Helmholtz National Medical Research Center of Eye Diseases, 105062 Moscow, Russia
| | - Rémi Eyraud
- Université Jean Monnet Saint-Etienne, CNRS, Institut d Optique Graduate School, Laboratoire Hubert Curien UMR 5516, 42023 Saint-Etienne, France
| | - François Devred
- Institut Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
| | - Marina V Serebryakova
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, 119992 Moscow, Russia
| | - Natalia G Shebardina
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, 119992 Moscow, Russia
| | - Dmitry V Chistyakov
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, 119992 Moscow, Russia
| | - Ivan I Senin
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, 119992 Moscow, Russia
| | - Vladimir A Mitkevich
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia
| | - Philipp O Tsvetkov
- Institut Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
| | - Evgeni Yu Zernii
- Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 1-40 Leninskye Gory, 119992 Moscow, Russia
| |
Collapse
|
4
|
Eyraud R, Ayache S, Tsvetkov PO, Kalidindi SS, Baksheeva VE, Boissonneau S, Jiguet-Jiglaire C, Appay R, Nanni-Metellus I, Chinot O, Devred F, Tabouret E. Plasma nanoDSF Denaturation Profile at Baseline Is Predictive of Glioblastoma EGFR Status. Cancers (Basel) 2023; 15:cancers15030760. [PMID: 36765718 PMCID: PMC9913157 DOI: 10.3390/cancers15030760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2022] [Revised: 01/05/2023] [Accepted: 01/18/2023] [Indexed: 01/28/2023] Open
Abstract
Glioblastoma (GBM) is the most frequent and aggressive primary brain tumor in adults. Recently, we demonstrated that plasma denaturation profiles of glioblastoma patients obtained using Differential Scanning Fluorimetry can be automatically distinguished from healthy controls with the help of Artificial Intelligence (AI). Here, we used a set of machine-learning algorithms to automatically classify plasma denaturation profiles of glioblastoma patients according to their EGFR status. We found that Adaboost AI is able to discriminate EGFR alterations in GBM with an 81.5% accuracy. Our study shows that the use of these plasma denaturation profiles could answer the unmet neuro-oncology need for diagnostic predictive biomarker in combination with brain MRI and clinical data, in order to allow for a rapid orientation of patients for a definitive pathological diagnosis and then treatment. We complete this study by showing that discriminating another mutation, MGMT, seems harder, and that post-surgery monitoring using our approach is not conclusive in the 48 h that follow the surgery.
Collapse
Affiliation(s)
- Rémi Eyraud
- Laboratoire Hubert Curien UMR 5516, UJM-Saint-Etienne, University Lyon, CNRS, 42000 Saint Etienne, France
| | | | - Philipp O. Tsvetkov
- Inst Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
- Plateforme Interactome Timone, PINT, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, 13005 Marseille, France
| | - Shanmugha Sri Kalidindi
- Laboratoire Hubert Curien UMR 5516, UJM-Saint-Etienne, University Lyon, CNRS, 42000 Saint Etienne, France
| | - Viktoriia E. Baksheeva
- Inst Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
| | | | - Carine Jiguet-Jiglaire
- Inst Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
- Department of Anatomopathology, Timone Hospital, APHM, 13005 Marseille, France
| | - Romain Appay
- Inst Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
- Department of Anatomopathology, Timone Hospital, APHM, 13005 Marseille, France
| | | | - Olivier Chinot
- Inst Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
- Service de Neurooncologie, CHU Timone, APHM, 13005 Marseille, France
| | - François Devred
- Inst Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
- Plateforme Interactome Timone, PINT, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, 13005 Marseille, France
- Correspondence: (F.D.); (E.T.)
| | - Emeline Tabouret
- Inst Neurophysiopathol, INP, Faculté des Sciences Médicales et Paramédicales, Aix Marseille Univ, CNRS, 13005 Marseille, France
- Service de Neurooncologie, CHU Timone, APHM, 13005 Marseille, France
- Correspondence: (F.D.); (E.T.)
| |
Collapse
|
5
|
Brain targeted delivery of carmustine using chitosan coated nanoparticles via nasal route for glioblastoma treatment. Int J Biol Macromol 2022; 221:435-445. [PMID: 36067850 DOI: 10.1016/j.ijbiomac.2022.08.210] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2022] [Revised: 08/25/2022] [Accepted: 08/31/2022] [Indexed: 11/24/2022]
Abstract
This study aims to develop chitosan-coated PLGA nanoparticles intended for nose-to-brain delivery of carmustine. Formulations were prepared by the double emulsion solvent evaporation method and optimized by using Box-Behnken Design. The optimized nanoparticles were obtained to satisfactory levels in terms of particle size, PDI, entrapment efficiency, and drug loading. In vitro drug release and ex-vivo permeation showed sustained release and enhanced permeability (approx. 2 fold) of carmustine compared to drug suspension. The AUC0-t of brain obtained with carmustine-loaded nanoparticles via nasal administration in Albino Wistar rats was 2.8 and 14.7 times that of intranasal carmustine suspension and intravenous carmustine, respectively. The MTT assay on U87 MG cell line showed a significant decrease (P < 0.05) in the IC50 value of the formulation (71.23 μg ml-1) as compared to drug suspension (90.02 μg ml-1).These findings suggest chitosan coated nanoparticles could be used to deliver carmustine via intranasal administration to treat Glioblastoma multiforme.
Collapse
|
6
|
Calorimetric Markers for Detection and Monitoring of Multiple Myeloma. Cancers (Basel) 2022; 14:cancers14163884. [PMID: 36010876 PMCID: PMC9405568 DOI: 10.3390/cancers14163884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/05/2022] [Accepted: 08/09/2022] [Indexed: 11/17/2022] Open
Abstract
Simple Summary This review highlights the potential of differential scanning calorimetry for multiple myeloma diagnosis and monitoring of the treatment outcome. The thermodynamic signatures of blood sera from patients with multiple myeloma are strongly dependent on the concentration and isotype of the secreted monoclonal immunoglobulins. Mathematical methods developed to analyze the biocalorimetry data and distinguish “diseased” from “healthy” thermogram to stratify plasma calorimetric profiles and determine specific interrelations between calorimetric and biochemical/clinical data are discussed. Abstract This review summarizes data obtained thus far on the application of differential scanning calorimetry (DSC) for the analysis of blood sera from patients diagnosed with multiple myeloma (MM) with the secretion of the most common isotypes of monoclonal proteins (M-proteins), free light chains (FLC) and non-secretory MM, as well as Waldenström macroglobulinemia and the premalignant state monoclonal gammopathy of undetermined significance. The heterogeneous nature of MM is reflected in the thermal stability profiles of the blood serum proteome of MM patients found to depend on both the level and the isotype of the secreted M-proteins or FLC. Common calorimetric markers feature the vast majority of the different myeloma types, i.e., stabilization of the major serum proteins and decrease in the albumin/globulin heat capacity ratio. A unique calorimetric fingerprint of FLC molecules forming amorphous aggregates is the low-temperature transition centered at 57 °C for a calorimetric set of FLC MM and at 46–47 °C for a single FLC MM case for which larger aggregates were formed. The calorimetric assay proved particularly advantageous for non-secretory MM and is thus a suitable tool for monitoring such patients during treatment courses. Thus, DSC provides a promising blood-based approach as a complementary tool for MM detection and monitoring.
Collapse
|
7
|
Liquid biopsy: early and accurate diagnosis of brain tumor. J Cancer Res Clin Oncol 2022; 148:2347-2373. [PMID: 35451698 DOI: 10.1007/s00432-022-04011-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 04/01/2022] [Indexed: 12/15/2022]
Abstract
Noninvasive examination is an emerging area in the field of neuro-oncology. Liquid biopsy captures the landscape of genomic alterations of brain tumors and revolutionizes the traditional diagnosis approaches. Rapidly changing sequencing technologies and more affordable prices put the screws on more application of liquid biopsy in clinical settings. In the past few years, extensive application of liquid biopsy has been seen throughout the whole diagnosis and treatment process of brain tumors, including early and accurate detection, characterization and dynamic monitoring. Here, we summarized and compared the most advanced techniques and target molecules or macrostructures related to brain tumor liquid biopsy. We further reviewed and emphasized recent progression in different clinical settings for brain tumors in blood and CSF. The preferred protocol, potential novel biomarkers and future development are discussed in the last part.
Collapse
|
8
|
Effect of a Ketogenic Diet on Oxidative Posttranslational Protein Modifications and Brain Homogenate Denaturation in the Kindling Model of Epilepsy in Mice. Neurochem Res 2022; 47:1943-1955. [PMID: 35316463 DOI: 10.1007/s11064-022-03579-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Revised: 03/10/2022] [Accepted: 03/12/2022] [Indexed: 10/18/2022]
Abstract
This study focused on the ketogenic diet (KD) effects on oxidative posttranslational protein modification (PPM) as presumptive factors implicated in epileptogenesis. A 28-day of KD treatment was performed. The corneal kindling model of epileptogenesis was used. Four groups of adult male ICR mice (25-30 g) were randomized in standard rodent chow (SRC) group, KD-treatment group; SRC + kindling group; KD + kindling group (n = 10 each). Advanced oxidation protein products (AOPP) and protein carbonyl contents of brain homogenates together with differential scanning calorimetry (DSC) were evaluated. Two exothermic transitions (Exo1 and Exo2) were explored after deconvolution of the thermograms. Factor analysis was applied. The protective effect of KD in the kindling model was demonstrated with both decreased seizure score and increased seizure latency. KD significantly decreased glucose and increased ketone bodies (KB) in blood. Despite its antiseizure effect, the KD increased the AOPP level and the brain proteome's exothermic transitions, suggestive for qualitative modifications. The ratio of the two exothermic peaks (Exo2/Exo1) of the thermograms from the KD vs. SRC treated group differed more than twice (3.7 vs. 1.6). Kindling introduced the opposite effect, changing this ratio to 2.7 for the KD + kindling group. Kindling significantly increased glucose and KB in the blood whereas decreased the BW under the SRC treatment. Kindling decreased carbonyl proteins in the brain irrespectively of the diet. Further evaluations are needed to assess the nature of correspondence of calorimetric images of the brain homogenates with PPM.
Collapse
|
9
|
Schneider G, Kaliappan A, Nguyen TQ, Buscaglia R, Brock GN, Hall MB, DeSpirito C, Wilkey DW, Merchant ML, Klein JB, Wiese TA, Rivas-Perez HL, Kloecker GH, Garbett NC. The Utility of Differential Scanning Calorimetry Curves of Blood Plasma for Diagnosis, Subtype Differentiation and Predicted Survival in Lung Cancer. Cancers (Basel) 2021; 13:5326. [PMID: 34771491 PMCID: PMC8582427 DOI: 10.3390/cancers13215326] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Revised: 10/17/2021] [Accepted: 10/19/2021] [Indexed: 11/16/2022] Open
Abstract
Early detection of lung cancer (LC) significantly increases the likelihood of successful treatment and improves LC survival rates. Currently, screening (mainly low-dose CT scans) is recommended for individuals at high risk. However, the recent increase in the number of LC cases unrelated to the well-known risk factors, and the high false-positive rate of low-dose CT, indicate a need to develop new, non-invasive methods for LC detection. Therefore, we evaluated the use of differential scanning calorimetry (DSC) for LC patients' diagnosis and predicted survival. Additionally, by applying mass spectrometry, we investigated whether changes in O- and N-glycosylation of plasma proteins could be an underlying mechanism responsible for observed differences in DSC curves of LC and control subjects. Our results indicate selected DSC curve features could be useful for differentiation of LC patients from controls with some capable of distinction between subtypes and stages of LC. DSC curve features also correlate with LC patients' overall/progression free survival. Moreover, the development of classification models combining patients' DSC curves with selected plasma protein glycosylation levels that changed in the presence of LC could improve the sensitivity and specificity of the detection of LC. With further optimization and development of the classification method, DSC could provide an accurate, non-invasive, radiation-free strategy for LC screening and diagnosis.
Collapse
Affiliation(s)
- Gabriela Schneider
- UofL Health—Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (G.S.); (A.K.); (T.Q.N.); (M.B.H.); (G.H.K.)
| | - Alagammai Kaliappan
- UofL Health—Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (G.S.); (A.K.); (T.Q.N.); (M.B.H.); (G.H.K.)
| | - Taylor Q. Nguyen
- UofL Health—Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (G.S.); (A.K.); (T.Q.N.); (M.B.H.); (G.H.K.)
| | - Robert Buscaglia
- Department of Mathematics and Statistics, Northern Arizona University, Flagstaff, AZ 86011, USA;
| | - Guy N. Brock
- Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA;
| | - Melissa Barousse Hall
- UofL Health—Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (G.S.); (A.K.); (T.Q.N.); (M.B.H.); (G.H.K.)
| | - Crissie DeSpirito
- Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (C.D.); (T.A.W.); (H.L.R.-P.)
| | - Daniel W. Wilkey
- Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (D.W.W.); (M.L.M.); (J.B.K.)
| | - Michael L. Merchant
- Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (D.W.W.); (M.L.M.); (J.B.K.)
| | - Jon B. Klein
- Division of Nephrology and Hypertension, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (D.W.W.); (M.L.M.); (J.B.K.)
- Robley Rex Veterans Affairs Medical Center, Louisville, KY 40202, USA
| | - Tanya A. Wiese
- Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (C.D.); (T.A.W.); (H.L.R.-P.)
| | - Hiram L. Rivas-Perez
- Division of Pulmonary, Critical Care and Sleep Disorders Medicine, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (C.D.); (T.A.W.); (H.L.R.-P.)
| | - Goetz H. Kloecker
- UofL Health—Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (G.S.); (A.K.); (T.Q.N.); (M.B.H.); (G.H.K.)
| | - Nichola C. Garbett
- UofL Health—Brown Cancer Center and Division of Medical Oncology and Hematology, Department of Medicine, University of Louisville, Louisville, KY 40202, USA; (G.S.); (A.K.); (T.Q.N.); (M.B.H.); (G.H.K.)
| |
Collapse
|
10
|
Todinova S, Krumova S, Bogdanova D, Danailova A, Zlatareva E, Kalaydzhiev N, Langari A, Milanov I, Taneva SG. Red Blood Cells' Thermodynamic Behavior in Neurodegenerative Pathologies and Aging. Biomolecules 2021; 11:biom11101500. [PMID: 34680133 PMCID: PMC8534019 DOI: 10.3390/biom11101500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 09/17/2021] [Accepted: 10/08/2021] [Indexed: 02/07/2023] Open
Abstract
The main trend of current research in neurodegenerative diseases (NDDs) is directed towards the discovery of novel biomarkers for disease diagnostics and progression. The pathological features of NDDs suggest that diagnostic markers can be found in peripheral fluids and cells. Herein, we investigated the thermodynamic behavior of the peripheral red blood cells (RBCs) derived from patients diagnosed with three common NDDs—Parkinson’s disease (PD), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS) and compared it with that of healthy individuals, evaluating both fresh and aged RBCs. We established that NDDs can be differentiated from the normal healthy state on the basis of the variation in the thermodynamic parameters of the unfolding of major RBCs proteins—the cytoplasmic hemoglobin (Hb) and the membrane Band 3 (B3) protein. A common feature of NDDs is the higher thermal stability of both Hb and B3 proteins along the RBCs aging, while the calorimetric enthalpy can distinguish PD from ALS and AD. Our data provide insights into the RBCs thermodynamic behavior in two complex and tightly related phenomena—neurodegenerative pathologies and aging, and it suggests that the determined thermodynamic parameters are fingerprints of the altered conformation of Hb and B3 protein and modified RBCs’ aging in the studied NDDs.
Collapse
Affiliation(s)
- Svetla Todinova
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev, 1113 Sofia, Bulgaria; (S.T.); (S.K.); (A.D.); (A.L.)
| | - Sashka Krumova
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev, 1113 Sofia, Bulgaria; (S.T.); (S.K.); (A.D.); (A.L.)
| | - Desislava Bogdanova
- Department of Neurology, University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sv. Naum, 1113 Sofia, Bulgaria; (D.B.); (E.Z.); (N.K.); (I.M.)
| | - Avgustina Danailova
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev, 1113 Sofia, Bulgaria; (S.T.); (S.K.); (A.D.); (A.L.)
| | - Elena Zlatareva
- Department of Neurology, University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sv. Naum, 1113 Sofia, Bulgaria; (D.B.); (E.Z.); (N.K.); (I.M.)
| | - Nikolay Kalaydzhiev
- Department of Neurology, University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sv. Naum, 1113 Sofia, Bulgaria; (D.B.); (E.Z.); (N.K.); (I.M.)
| | - Ariana Langari
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev, 1113 Sofia, Bulgaria; (S.T.); (S.K.); (A.D.); (A.L.)
| | - Ivan Milanov
- Department of Neurology, University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry Sv. Naum, 1113 Sofia, Bulgaria; (D.B.); (E.Z.); (N.K.); (I.M.)
| | - Stefka G. Taneva
- Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Acad. G. Bonchev, 1113 Sofia, Bulgaria; (S.T.); (S.K.); (A.D.); (A.L.)
- Correspondence:
| |
Collapse
|
11
|
Williams S, Layard Horsfall H, Funnell JP, Hanrahan JG, Khan DZ, Muirhead W, Stoyanov D, Marcus HJ. Artificial Intelligence in Brain Tumour Surgery-An Emerging Paradigm. Cancers (Basel) 2021; 13:cancers13195010. [PMID: 34638495 PMCID: PMC8508169 DOI: 10.3390/cancers13195010] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 10/02/2021] [Accepted: 10/03/2021] [Indexed: 01/01/2023] Open
Abstract
Artificial intelligence (AI) platforms have the potential to cause a paradigm shift in brain tumour surgery. Brain tumour surgery augmented with AI can result in safer and more effective treatment. In this review article, we explore the current and future role of AI in patients undergoing brain tumour surgery, including aiding diagnosis, optimising the surgical plan, providing support during the operation, and better predicting the prognosis. Finally, we discuss barriers to the successful clinical implementation, the ethical concerns, and we provide our perspective on how the field could be advanced.
Collapse
Affiliation(s)
- Simon Williams
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; (H.L.H.); (J.P.F.); (J.G.H.); (D.Z.K.); (W.M.); (H.J.M.)
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
- Correspondence:
| | - Hugo Layard Horsfall
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; (H.L.H.); (J.P.F.); (J.G.H.); (D.Z.K.); (W.M.); (H.J.M.)
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
| | - Jonathan P. Funnell
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; (H.L.H.); (J.P.F.); (J.G.H.); (D.Z.K.); (W.M.); (H.J.M.)
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
| | - John G. Hanrahan
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; (H.L.H.); (J.P.F.); (J.G.H.); (D.Z.K.); (W.M.); (H.J.M.)
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
| | - Danyal Z. Khan
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; (H.L.H.); (J.P.F.); (J.G.H.); (D.Z.K.); (W.M.); (H.J.M.)
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
| | - William Muirhead
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; (H.L.H.); (J.P.F.); (J.G.H.); (D.Z.K.); (W.M.); (H.J.M.)
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
| | - Danail Stoyanov
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
| | - Hani J. Marcus
- Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK; (H.L.H.); (J.P.F.); (J.G.H.); (D.Z.K.); (W.M.); (H.J.M.)
- Wellcome/Engineering and Physical Sciences Research Council (EPSRC) Centre for Interventional and Surgical Sciences (WEISS), London W1W 7TY, UK;
| |
Collapse
|
12
|
Annesi F, Hermoso-Durán S, Rizzuti B, Bruno R, Pirritano D, Petrone A, Del Giudice F, Ojeda J, Vega S, Sanchez-Gracia O, Velazquez-Campoy A, Abian O, Guzzi R. Thermal Liquid Biopsy (TLB) of Blood Plasma as a Potential Tool to Help in the Early Diagnosis of Multiple Sclerosis. J Pers Med 2021; 11:jpm11040295. [PMID: 33924346 PMCID: PMC8069382 DOI: 10.3390/jpm11040295] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Revised: 03/31/2021] [Accepted: 04/09/2021] [Indexed: 12/21/2022] Open
Abstract
Background: Multiple sclerosis (MS) is frequently characterized by a variety of clinical signs, often exhibiting little specificity. The diagnosis requires a combination of medical observations and instrumental tests, and any support for its objective assessment is helpful. Objective: Herein, we describe the application of thermal liquid biopsy (TLB) of blood plasma samples, a methodology for predicting the occurrence of MS with a noninvasive, quick blood test. Methods: TLB allows one to define an index (TLB score), which provides information about overall real-time alterations in plasma proteome that may be indicative of MS. Results: This pilot study, based on 85 subjects (45 MS patients and 40 controls), showed good performance indexes (sensitivity and specificity both around 70%). The diagnostic methods better discriminate between early stage and low-burden MS patients, and it is not influenced by gender, age, or assumption of therapeutic drugs. TLB is more accurate for patients having low disability level (≤ 3.0, measured by the expanded disability status scale, EDSS) and a relapsing–remitting diagnosis. Conclusion: Our results suggest that TLB can be applied to MS, especially in an initial phase of the disease when diagnosis is difficult and yet more important (in such cases, accuracy of prediction is close to 80%), as well as in personalized patient periodic monitoring. The next step will be determining its utility in differentiating between MS and other disorders, in particular in inflammatory diseases.
Collapse
Affiliation(s)
- Ferdinanda Annesi
- CNR-NANOTEC, Licryl-UOS Cosenza and CEMIF.Cal, Department of Physics, University of Calabria, 87036 Rende, Italy; (F.A.); (B.R.)
| | - Sonia Hermoso-Durán
- Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain; (S.H.-D.); (S.V.); (A.V.-C.)
- Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain
| | - Bruno Rizzuti
- CNR-NANOTEC, Licryl-UOS Cosenza and CEMIF.Cal, Department of Physics, University of Calabria, 87036 Rende, Italy; (F.A.); (B.R.)
- Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain; (S.H.-D.); (S.V.); (A.V.-C.)
| | - Rosalinda Bruno
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy;
| | - Domenico Pirritano
- Neurological and Stroke Unit, Multiple Sclerosis Clinic, Annunziata Hospital, 87100 Cosenza, Italy; (D.P.); (A.P.); (F.D.G.)
| | - Alfredo Petrone
- Neurological and Stroke Unit, Multiple Sclerosis Clinic, Annunziata Hospital, 87100 Cosenza, Italy; (D.P.); (A.P.); (F.D.G.)
| | - Francesco Del Giudice
- Neurological and Stroke Unit, Multiple Sclerosis Clinic, Annunziata Hospital, 87100 Cosenza, Italy; (D.P.); (A.P.); (F.D.G.)
| | - Jorge Ojeda
- Department of Statistical Methods, Universidad de Zaragoza, 50009 Zaragoza, Spain;
| | - Sonia Vega
- Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain; (S.H.-D.); (S.V.); (A.V.-C.)
| | | | - Adrian Velazquez-Campoy
- Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain; (S.H.-D.); (S.V.); (A.V.-C.)
- Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain
- Departamento de Bioquímica y Biología Molecular y Celular, Universidad de Zaragoza, 50009 Zaragoza, Spain
- Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain
- Fundación ARAID, Gobierno de Aragón, 50009 Zaragoza, Spain
| | - Olga Abian
- Institute of Biocomputation and Physics of Complex Systems (BIFI), Joint Units IQFR-CSIC-BIFI, and GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain; (S.H.-D.); (S.V.); (A.V.-C.)
- Instituto de Investigación Sanitaria Aragón (IIS Aragón), 50009 Zaragoza, Spain
- Departamento de Bioquímica y Biología Molecular y Celular, Universidad de Zaragoza, 50009 Zaragoza, Spain
- Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain
- Instituto Aragonés de Ciencias de la Salud (IACS), 50009 Zaragoza, Spain
- Correspondence: (O.A.); (R.G.); Tel.: +34-876-555417 (O.A.); +39-0984-406077 (R.G.)
| | - Rita Guzzi
- CNR-NANOTEC, Licryl-UOS Cosenza and CEMIF.Cal, Department of Physics, University of Calabria, 87036 Rende, Italy; (F.A.); (B.R.)
- Department of Physics, Molecular Biophysics Laboratory, University of Calabria, 87036 Rende, Italy
- Correspondence: (O.A.); (R.G.); Tel.: +34-876-555417 (O.A.); +39-0984-406077 (R.G.)
| |
Collapse
|
13
|
Tsvetkov PO, Eyraud R, Ayache S, Bougaev AA, Malesinski S, Benazha H, Gorokhova S, Buffat C, Dehais C, Sanson M, Bielle F, Figarella Branger D, Chinot O, Tabouret E, Devred F. An AI-Powered Blood Test to Detect Cancer Using NanoDSF. Cancers (Basel) 2021; 13:cancers13061294. [PMID: 33803924 PMCID: PMC7999960 DOI: 10.3390/cancers13061294] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Revised: 03/01/2021] [Accepted: 03/03/2021] [Indexed: 12/12/2022] Open
Abstract
Glioblastoma is the most frequent and aggressive primary brain tumor. Its diagnosis is based on resection or biopsy that could be especially difficult and dangerous in the case of deep location or patient comorbidities. Monitoring disease evolution and progression also requires repeated biopsies that are often not feasible. Therefore, there is an urgent need to develop biomarkers to diagnose and follow glioblastoma evolution in a minimally invasive way. In the present study, we described a novel cancer detection method based on plasma denaturation profiles obtained by a non-conventional use of differential scanning fluorimetry. Using blood samples from 84 glioma patients and 63 healthy controls, we showed that their denaturation profiles can be automatically distinguished with the help of machine learning algorithms with 92% accuracy. Proposed high throughput workflow can be applied to any type of cancer and could become a powerful pan-cancer diagnostic and monitoring tool requiring only a simple blood test.
Collapse
Affiliation(s)
- Philipp O. Tsvetkov
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Faculté des Sciences Médicales et Paramédicales, Plateforme Interactome Timone, PINT, Aix Marseille Univ, 13009 Marseille, France
- Correspondence: (P.O.T.); (F.D.)
| | - Rémi Eyraud
- Laboratoire Hubert Curien UMR 5516, UJM-Saint-Etienne, CNRS, University Lyon, 42000 Saint Etienne, France;
| | - Stéphane Ayache
- CNRS, LIS, Aix-Marseille Univ, 13009 Marseille, France; (S.A.); (H.B.)
| | | | - Soazig Malesinski
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
| | - Hamed Benazha
- CNRS, LIS, Aix-Marseille Univ, 13009 Marseille, France; (S.A.); (H.B.)
| | - Svetlana Gorokhova
- MMG, INSERM, Aix-Marseille Univ, 13009 Marseille, France;
- Service de génétique Médicale, Hôpital de La Timone, APHM, 13005 Marseille, France
| | - Christophe Buffat
- Biochemistry and Endocrinology, Hôpital de la Conception, APHM, 13005 Marseille, France;
- MEPHI, IRD, APHM, Aix-Marseille Univ, 13274 Marseille, France
| | - Caroline Dehais
- CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm, F-75006 Paris, France; (C.D.); (M.S.); (F.B.)
- Service de Neurologie 2-Mazarin, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
| | - Marc Sanson
- CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm, F-75006 Paris, France; (C.D.); (M.S.); (F.B.)
- Service de Neurologie 2-Mazarin, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
| | - Franck Bielle
- CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, Sorbonne Université, Inserm, F-75006 Paris, France; (C.D.); (M.S.); (F.B.)
- Département de Neuropathologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière—Charles Foix, F-75013 Paris, France
| | - Dominique Figarella Branger
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Service d’Anatomie Pathologique et de Neuropathologie, CHU Timone, APHM, 13005 Marseille, France
| | - Olivier Chinot
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Service de Neuro Oncologie, Hopital de La Timone, APHM, 13005 Marseille, France
| | - Emeline Tabouret
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Service de Neuro Oncologie, Hopital de La Timone, APHM, 13005 Marseille, France
| | - François Devred
- Faculté des Sciences Médicales et Paramédicales, Inst Neurophysiopathol, CNRS, INP, Aix Marseille Univ, 13005 Marseille, France; (S.M.); (D.F.B.); (O.C.); (E.T.)
- Faculté des Sciences Médicales et Paramédicales, Plateforme Interactome Timone, PINT, Aix Marseille Univ, 13009 Marseille, France
- Correspondence: (P.O.T.); (F.D.)
| |
Collapse
|
14
|
Antonova B, Naydenov E, Koynova R, Tumangelova-Yuzeir K, Tenchov B. Exothermic transitions in the heat capacity profiles of human cerebrospinal fluid. EUROPEAN BIOPHYSICS JOURNAL : EBJ 2020; 49:231-238. [PMID: 32172413 DOI: 10.1007/s00249-020-01429-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 02/18/2020] [Accepted: 03/01/2020] [Indexed: 01/24/2023]
Abstract
In this work, we examined by DSC protein denaturation heat capacity profiles for two body fluids, cerebrospinal fluid (CSF) and blood plasma obtained from brain tumor (mainly glioblastoma) patients and healthy volunteers. We observed large distinctions between the heat capacity profiles of CSF and blood plasma, although their protein compositions are believed to have much in common. A prominent, previously unreported CSF feature was the existence of a pre-denaturation exothermic transition peaking at ~ 50-52 °C, recorded for both control and brain tumor CSF. This appears to be the first observation of a pre-denaturation exotherm in a human body fluid. In all studied samples, the exotherms deconvoluted with high precision into a sum of two Gaussian peaks. These exotherms are apparently specific, originating from brain tissue-soluble proteins in the CSF not present in blood plasma. Malignant brain tumors (glioblastoma multiforme, Grade IV, and low-grade glioma, Grade II) reduced twofold the enthalpy of the exotherms relative to the control. These results suggest that the amount and/or conformational state of the CSF proteins (e.g., intrinsic disorder) giving rise to pre-denaturation exothermic events substantially changed upon brain tumor progression. Concomitantly, the enthalpy of the CSF endothermic peaks was partially redistributed from a lower-temperature (main) transition to a higher-temperature transition. The presented data demonstrated that the heat capacity profiles of intrinsic CSF proteins constitute a sensitive biomarker of glioblastoma and other brain malignancies.
Collapse
Affiliation(s)
- Borislava Antonova
- Department of Medical Physics and Biophysics, Medical University-Sofia, 1431, Sofia, Bulgaria
| | - Emanuil Naydenov
- Department of Neurosurgery, University Hospital "St. Ivan Rilski", Medical University-Sofia, 1431, Sofia, Bulgaria
| | - Rumiana Koynova
- Ohio State University College of Pharmacy, Columbus, OH, 43210, USA
| | - Kalina Tumangelova-Yuzeir
- Laboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Medical University-Sofia, 1431, Sofia, Bulgaria
| | - Boris Tenchov
- Department of Medical Physics and Biophysics, Medical University-Sofia, 1431, Sofia, Bulgaria.
| |
Collapse
|
15
|
Tsvetkov PO, Devred F. Plasmatic Signature of Disease by Differential Scanning Calorimetry (DSC). Methods Mol Biol 2019; 1964:45-57. [PMID: 30929234 DOI: 10.1007/978-1-4939-9179-2_4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Differential scanning calorimetry (DSC) has been used for several decades to characterize thermal stability of macromolecules such as proteins and DNA. It allows to determine the denaturation temperature and enthalpy of individual domains of proteins, thus giving new insights into their domain organization and ligand interaction. Over the past decade, it has been shown that this technique can also be used to study biofluids such as plasma or cerebrospinal fluid to obtain denaturation profiles. An increasing number of studies demonstrated that such profiles obtained from patients were significantly different from profiles obtained using biofluids of healthy individuals. This opens interesting perspectives for new diagnostics and monitoring tools for a large number of diseases. Nevertheless, the extensive studies of plasma samples from patients with different pathologies as well as the development of standardized methods of data analysis are necessary to reach the promising diagnostic potential of this methodology. Using plasma samples from healthy individuals and glioblastoma patients, we outline the steps necessary to obtain a plasmatic calorimetric profile with VP-DSC instrument and describe a cluster analysis of obtained data.
Collapse
Affiliation(s)
- Philipp O Tsvetkov
- Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Fac Pharm, Marseille, France
| | - François Devred
- Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Fac Pharm, Marseille, France.
| |
Collapse
|